Update on GSK hepatitis vaccine availability
03 November 2017
The following GSK hepatitis containing vaccines are experiencing supply constraints. We expect to provide the next update on supply of these vaccines in early December 2017.
- Twinrix adult (combined hepatitis A and hepatitis B vaccine)
- Twinrix junior (combined hepatitis A and hepatitis B vaccine)
- Engerix-B paediatric (hepatitis B surface antigen recombinant (yeast) vaccine)
Engerix-B adult (hepatitis B surface antigen recombinant (yeast) vaccine)
This vaccine is experiencing a long term supply constraint in Australia due to a disruption in the manufacturing process. Production is now back to normal, however it will take time to re-build capacity. We expect to provide the next update on supply of this vaccine in 2018.
GSK prioritises hepatitis B vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Engerix-B to all Australian State, Territory and Federal Government vaccination programs where Engerix-B is the vaccine of choice.
We understand that these stock-outs may be distressing for those who are not covered by government programs and who may be required to vaccinate themselves for occupational reasons or because they are planning on travelling to hepatitis-affected areas.
Please visit the TGA website for ongoing updates to supply.
For more information, please contact GSK medical information on 1800 033 109.